- 专利标题： Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method
-
申请号： US15509269申请日： 2015-09-08
-
公开(公告)号： US10471146B2公开(公告)日： 2019-11-12
- 发明人: Yasuhiro Matsumura , Masahiro Yasunaga , Shinji Saijou , Shingo Hanaoka
- 申请人： National Cancer Center , RIN Institute Inc.
- 申请人地址： JP Tokyo JP Tokyo
- 专利权人： National Cancer Center,RIN Institute Inc.
- 当前专利权人： National Cancer Center,RIN Institute Inc.
- 当前专利权人地址： JP Tokyo JP Tokyo
- 代理机构： Candy + Lortz LLP
- 代理商 Suzannah K. Sundby, Esq.
- 优先权： JP2014-182760 20140908; JP2014-260727 20141224
- 国际申请： PCT/JP2015/075425 WO 20150908
- 国际公布： WO2016/039321 WO 20160317
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; G01N33/577 ; C07K16/30 ; C12N15/13 ; C07K16/18 ; G01N33/574 ; A61K39/00
摘要：
An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.
公开/授权文献
信息查询
